A new, high-quality study reveals that the cardioprotective drug dexrazoxane significantly reduces the heart damage caused by chemotherapy received by pediatric cancer patients 15 years or more after treatment ends.
The research, which builds on previous studies at earlier follow-up times, is the first large, long-term study suggesting that receiving dexrazoxane may change how doctors should follow survivors for decades after treatment. The findings could also help steer prescribing recommendations while providing families and patients with some reassurance about the long-term effects of cancer treatment on young patients.
Read more about Protective Drug Dexrazoxane Reduces Heart Damage in Pediatric Cancer Survivors Years After Treatment Ends.
